Abstract
Abstract
Purpose of Review
This review aims to summarize the most recent published literature concerning lomitapide and volanesorsen that are approved for the use in HoFH and FCS patients, respectively. Moreover, it will briefly revise the published evidence on novel, non-approved treatments that are under evaluation for the management of these rare forms of dyslipidemias
Recent Findings
The definition of rare dyslipidemias identifies a large number of severe disorders of lipid metabolism of genetic origin. Among them were homozygous familial hypercholesterolemia (HoFH) (OMIM #143890) and familial chylomicronemia syndrome (FCS) (OMIM #238600), which are characterized by a markedly impaired cholesterol- and triglyceride-containing lipoproteins metabolism. They are being particularly associated with poor health outcomes and quality of life. Considering the severity of these diseases, common lipid-lowering drugs are often ineffective or do not allow to achieve the recommended lipid targets to prevent the development of complications. Nowadays, several new drugs have been found to effectively treat HoFH and FCS with an acceptable safety profile.
Summary
Treating patients with HoFH and FCS remains very challenging. However, novel treatment options are emerging and might be considered in addition to conventional therapy for managing these diseases. These novel drugs will possibly change the natural history of these two rare and life-threatening diseases.
Funder
Università degli Studi di Roma La Sapienza
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Reference64 articles.
1. Hegele RA, Borén J, Ginsberg HN, Arca M, Averna M, Binder CJ, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020;8(1):50–67. https://doi.org/10.1016/S2213-8587(19)30264-5.
2. Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016;4(10):850–61. https://doi.org/10.1016/S2213-8587(16)30041-9.
3. Stefanutti C. Lomitapide–a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia. Vol. 22, Current Atherosclerosis Reports. Springer; 2020 [cited 2021 Feb 14]. Available from: /pmc/articles/PMC7303073/.
4. Bertolini S, Calandra S, Arca M, Averna M, Catapano AL, Tarugi P, et al. Homozygous familial hypercholesterolemia in Italy: clinical and molecular features. Atherosclerosis. 2020 Nov 1 [cited 2021 May 20];312:72–8. Available from: https://moh-it.pure.elsevier.com/en/publications/homozygous-familial-hypercholesterolemia-in-italy-clinical-and-mo-2.
5. Sirinian MI, Belleudi F, Campagna F, Ceridono M, Garofalo T, Quagliarini F, et al. Adaptor protein ARH is recruited to the plasma membrane by low density lipoprotein (LDL) binding and modulates endocytosis of the LDL/LDL receptor complex in hepatocytes. J Biol Chem. 2005 [cited 2021 May 31];280(46):38416–23. Available from: https://pubmed.ncbi.nlm.nih.gov/16129683/.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献